SMAD3 and coronary artery disorder: Far higher TGF-β1 and SMAD3 concentrations occurred in CAD patients (TGF-β1: 432.2 ± 22.12 ng/L; SMAD3: 11.47 ± 0.6161 ng/L) compared with controls (TGF-β1: 220.1 ± 8.831 ng/L; SMAD3: 5.157 ± 0.1965 ng/L).